Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

366 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of cognitive symptoms in post COVID-19 patients.
Ruzicka M, Sachenbacher S, Heimkes F, Uebleis AO, Karch S, Grosse-Wentrup F, Ibarra Fonseca GJ, Wunderlich N, Bogner J, Mayerle J, von Bergwelt-Baildon M, Falkai P, Subklewe M, Ruzicka T, Benesch C, Valdinoci E, Pernpruner A, Thomas A, Heindl B, Stubbe HC, Adorjan K. Ruzicka M, et al. Eur Arch Psychiatry Clin Neurosci. 2024 Dec;274(8):1923-1934. doi: 10.1007/s00406-024-01821-z. Epub 2024 May 13. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 38739263 Free PMC article.
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Bücklein VL, Ruzicka M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1406-1413. doi: 10.1007/s00259-022-06075-2. Epub 2022 Dec 14. Eur J Nucl Med Mol Imaging. 2023. PMID: 36513818
Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy.
Fan J, Adams A, Sieg N, Heger JM, Gödel P, Kutsch N, Kaul D, Teichert M, von Tresckow B, Bücklein V, Goesmann G, Li M, Struve N, Trommer M, Linde P, Rosenbrock J, Celik E, Penack O, Stuschke M, Subklewe M, Belka C, von Bergwelt-Baildon M, Borchmann P, Marnitz S, Baues C. Fan J, et al. Radiother Oncol. 2023 Jun;183:109580. doi: 10.1016/j.radonc.2023.109580. Epub 2023 Feb 25. Radiother Oncol. 2023. PMID: 36842663
Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer.
Dorman K, Boeck S, Snijder RJ, Siveke JT, Schenk M, Mayerle J, Caca K, Freiberg-Richter J, Fischer von Weikersthal L, Kullmann F, Reinacher-Schick A, Fuchs M, Kanzler S, Kunzmann V, Ettrich TJ, Zhang D, Held S, Abdul-Ahad A, von Bergwelt-Baildon M, Heinemann V, Haas M. Dorman K, et al. Curr Oncol. 2023 Jun 17;30(6):5828-5834. doi: 10.3390/curroncol30060436. Curr Oncol. 2023. PMID: 37366919 Free PMC article.
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
Weiss L, Heinemann V, Fischer LE, Gieseler F, Hoehler T, Mayerle J, Quietzsch D, Reinacher-Schick A, Schenk M, Seipelt G, Siveke JT, Stahl M, Vehling-Kaiser U, Waldschmidt DT, Dorman K, Zhang D, Westphalen CB, von Bergwelt-Baildon M, Boeck S, Haas M. Weiss L, et al. Clin Transl Oncol. 2024 May;26(5):1268-1272. doi: 10.1007/s12094-023-03323-1. Epub 2023 Oct 4. Clin Transl Oncol. 2024. PMID: 37794220 Free PMC article.
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bücklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Ann Hematol. 2024 Jan;103(1):259-268. doi: 10.1007/s00277-023-05507-9. Epub 2023 Oct 20. Ann Hematol. 2024. PMID: 37861736
Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bücklein V, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. J Immunother Cancer. 2023 Oct;11(10):e006659. doi: 10.1136/jitc-2022-006659. J Immunother Cancer. 2023. PMID: 37880181 Free PMC article.
366 results